Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Affiliations

• ¹ Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, North Carolina, USA.
• ² Churchill Hospital, Oxford University, Oxford, UK.
• ³ Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
• ⁴ Columbia University, New York, New York, USA.
• ⁵ AbbVie Inc., North Chicago, Illinois, USA.
• ⁶ University of California Irvine, Irvine, California, USA.
• ⁷ Fred Hutchinson Cancer Research Center, Seattle, Washington State, USA.
• ⁸ John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey, USA.
• ⁹ CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
• ¹⁰ Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
• ¹¹ Lymphoma and CLL Program, Novant Health Cancer Institute, Charlotte, North Carolina, USA.
• ¹² Hôpital Maisonneuve-Rosemont, University of Montreal, Canada.
• ¹³ Cleveland Clinic, Cleveland, Ohio, USA.
• ¹⁴ Nottingham University Hospitals, NHS Trust, Nottingham, UK.
• ¹⁵ Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.
• ¹⁶ University of Massachusetts, Worcester, Massachusetts, USA.
• ¹⁷ Dartmouth Cancer Center, Lebanon, New Hampshire, USA.
• ¹⁸ Tufts Medical Center, Boston, Massachusetts, USA.
• ¹⁹ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
• ²⁰ Stanford Cancer Institute, Stanford University, Stanford, California, USA.
• ²¹ University of Pennsylvania, Philadelphia, Pennsylvania, USA.
• ²² Lowell General Hospital, Lowell, Massachusetts, USA.
• ²³ Analysis Group Inc., Montreal, Quebec, Canada.